|
| 37935977 | A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. | Leukemia | 2024 |
| 37994196 | Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. | Am J Hematol | 2024 |
| 37946611 | Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. | Br J Haematol | 2024 |
| 37646654 | Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. | Haematologica | 2024 |
| 36215988 | Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. | Lancet Haematol | 2023 |
| 37808770 | IL-1β-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes. | bioRxiv | 2023 |
| 37635400 | Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. | Am J Hematol | 2023 |
| 37752285 | Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. | Leukemia | 2023 |
| 37665752 | Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. | Am J Hematol | 2023 |
| 37854355 | The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. | Ther Adv Hematol | 2023 |
| 37703506 | Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. | J Clin Oncol | 2023 |
| 37585491 | Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. | Clin Cancer Res | 2023 |
| 37515433 | Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. | Am J Hematol | 2023 |
| 37841255 | Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. | Front Immunol | 2023 |
| 37735426 | Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. | Blood Cancer J | 2023 |
| 37690903 | Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37608562 | Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. | Br J Haematol | 2023 |
| 35833298 | Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. | Haematologica | 2023 |
| 35633516 | Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. | Am J Hematol | 2023 |
| 36951293 | Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. | Br J Haematol | 2023 |
| 36951163 | Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). | Haematologica | 2023 |
| 37422688 | A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. | J Hematol Oncol | 2023 |
| 37086851 | Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. | Transplant Cell Ther | 2023 |
| 37288607 | Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. | Am J Hematol | 2023 |
| 37187201 | Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. | Lancet Haematol | 2023 |
| 36990622 | Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. | Lancet Haematol | 2023 |
| 36990279 | Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. | Mod Pathol | 2023 |
| 37386016 | A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. | Blood Cancer J | 2023 |
| 37185307 | Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. | Leukemia | 2023 |
| 36988276 | Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. | Clin Cancer Res | 2023 |
| 37046645 | Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. | Cancers (Basel) | 2023 |
| 37311468 | Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. | Lancet | 2023 |
| 37441846 | Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. | Blood | 2023 |
| 37308342 | Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37102976 | A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. | Blood Cancer Discov | 2023 |
| 37334870 | Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. | Am J Hematol | 2023 |
| 37131217 | Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. | J Hematol Oncol | 2023 |
| 37066354 | Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemia. | bioRxiv | 2023 |
| 36888930 | Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. | J Clin Oncol | 2023 |
| 36884300 | Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. | Blood Adv | 2023 |
| 36724453 | Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. | Blood | 2023 |
| 36882573 | Association between bariatric surgery and outcomes in chronic myeloid leukemia. | Cancer | 2023 |
| 36787738 | Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. | Cell Rep Med | 2023 |
| 36402146 | Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. | Lancet Haematol | 2023 |
| 36715486 | Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. | Cancer | 2023 |
| 36436780 | Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. | Transplant Cell Ther | 2023 |
| 36683287 | The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. | Am J Hematol | 2023 |
| 36682988 | SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. | Clin Lymphoma Myeloma Leuk | 2023 |
| 36428152 | Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. | Clin Lymphoma Myeloma Leuk | 2023 |
| 36801700 | PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. | Leuk Res | 2023 |